<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2101256692
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CELLONA 500 mg F.C.TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MYCOPHENOLATE MOFETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        583.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Kocak Farma &#x130;lac Ve Kimya Sanayi A.S." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Kocak Farma İlac Ve Kimya Sanayi A.S.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA06 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cellona contains mycophenolate mofetil.</p><p>&bull; This belongs to a group of medicines called &ldquo;immunosuppressants&rdquo;. Cellona is used to prevent your body rejecting a transplanted organ.</p><p>&bull; A kidney, heart or liver. Cellona should be used together with other medicines:</p><p>&bull; Ciclosporin</p><p>&bull; Corticosteroids.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>WARNING</p><p>Mycophenolate causes birth defects and miscarriage. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor will speak to you and give you written information, particularly on the effects of mycophenolate on unborn babies. Read the information carefully and follow the instructions.&nbsp;</p><p>If you do not fully understand these instructions, please ask your doctor to explain them again before you take mycophenolate. See also further information in this section under &ldquo;Warnings and precautions&rdquo; and &ldquo;Pregnancy and breast-feeding&rdquo;.</p><p><strong>Do not take Cellona if: </strong></p><p>&bull; You are allergic to mycophenolate mofetil, mycophenolic acid or any of the other ingredients of Cellona (listed in Section 6)</p><p>&bull; If you are a woman who could be pregnant, and you have not provided a negative pregnancy test before your first prescription as mycophenolate causes birth defects and miscarriage. &bull; If you are pregnant or planning to become pregnant or think you may be pregnant.</p><p>&bull; If you are not using effective contraception (see Pregnancy, contraception and breastfeeding).</p><p>&bull; If you are breast-feeding.</p><p>Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Cellona.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor straight away before taking Cellona if:</p><p>&bull; You have a sign of infection such as a fever or sore throat &bull; You have any unexpected bruising or bleeding</p><p>&bull; You have ever had a problem with your digestive system such as a stomach ulcer</p><p>&bull; You are planning to become pregnant or if you get pregnant while taking Cellona.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor straight away before taking Cellona.</p><p><strong>The effect of sunlight </strong></p><p>Cellona reduces your body&rsquo;s defenses. As a result, there is an increased risk of skin cancer. Limit the amount of sunlight and UV light you get. Do this by:</p><p>&bull; wearing protective clothing which also covers your head, neck, arms and legs</p><p>&bull; using a sunscreen with a high protection factor.</p><p><strong>Other medicines and Cellona</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken, any other medicines.</p><p>This includes medicines obtained without a prescription, including herbal medicines.</p><p>This is because Cellona can affect the way some other medicines work. Also other medicines can affect the way Cellona works. In particular, tell your doctor or pharmacist if you are taking any of the following medicines before you start Cellona:</p><p>&bull; Azathioprine or other medicines which suppress your immune system &ndash; given after a transplant operation</p><p>&bull; Cholestyramine &ndash; used to treat high cholesterol</p><p>&bull; Rifampicin &ndash; an antibiotic used to prevent and treat infections such as tuberculosis (TB)</p><p>&bull; Antacids, or proton pump inhibitors &ndash; used for acid problems in your stomach such as indigestion</p><p>&bull; Phosphate binders &ndash; used by people with chronic kidney failure to reduce how much phosphate gets absorbed into their blood.</p><p>&bull; Antibiotics &ndash; used to treat bacterial infections</p><p>&bull; Isavuconazole &ndash; used to treat fungal infections</p><p>&bull; Telmisartan &ndash; used to treat high blood pressure</p><p><strong>Vaccines </strong></p><p>If you need to have a vaccine (a live vaccine) while taking Cellona, talk to your doctor or pharmacist first. Your doctor will have to advise you on what vaccines you can have. You must not donate blood during treatment with Cellona and for at least 6 weeks after stopping treatment. Men must not donate semen during treatment with Cellona and for at least 90 days after stopping treatment.</p><p><strong>Cellona with food and drink </strong></p><p>Taking food and drink has no effect on your treatment with Cellona.</p><p><strong>Pregnancy, contraception and breast-feeding </strong></p><p>Contraception in women taking Cellona If you are a woman who could become pregnant you must use an effective method of contraception with Cellona. This includes:</p><p>&bull; Before you start taking Cellona</p><p>&bull; During your entire treatment with Cellona</p><p>&bull; For 6 weeks after you stop taking Cellona Talk to your doctor about the most suitable contraception for you.</p><p>This will depend on your individual situation. Two forms of contraception are preferable as this will reduce the risk of unintended pregnancy.<strong>Contact your doctor as soon as possible, if you think your contraception may not have been effective or if you have forgotten to take your contraceptive pill.</strong> You are a woman who is not capable of becoming pregnant if any of the following applies to you:</p><p>&bull; You are post-menopausal, i.e. at least 50 years old and your last period was more than a year ago (if your periods have stopped because you have had treatment for cancer, then there is still a chance you could become pregnant)</p><p>&bull; Your fallopian tubes and both ovaries have been removed by surgery (bilateral salpingooophorectomy)</p><p>&bull; Your womb (uterus) has been removed by surgery (hysterectomy)</p><p>&bull; Your ovaries no longer work (premature ovarian failure, which has been confirmed by a specialist gynaecologist)</p><p>&bull; You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner&rsquo;s syndrome or uterine agenesis</p><p>&bull; You are a child or teenager who has not started having periods.</p><p><strong>Contraception in men taking Cellona </strong></p><p>The available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate. However, a risk cannot be completely excluded. As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90 days after you stop taking Cellona. If you are planning to have a child, talk to your doctor about the potential risks.&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will talk to you about the risks in case of pregnancy and the alternatives you can take to prevent rejection of your transplant organ if: &bull; You plan to become pregnant. &bull; You miss or think you have missed a period, or you have unusual menstrual bleeding, or suspect you are pregnant. &bull; You have sex without using an effective method of contraception. If you do become pregnant during the treatment with mycophenolate, you must inform your doctor immediately. However, keep taking Cellona until you see him or her.&nbsp;</p><p><strong>Pregnancy </strong></p><p>Mycophenolate causes a very high frequency of miscarriage (50%) and of severe birth defects (23-27 %) in the unborn baby. Birth defects which have been reported include anomalies of ears, of eyes, of face (cleft lip/palate), of development of fingers, of heart, oesophagus (tube that connects the throat with the stomach), kidneys and nervous system (for example spina bifida (where the bones of the spine are not properly developed)). Your baby may be affected by one or more of these. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor may request more than one test to ensure you are not pregnant before starting treatment.</p><p><strong>Breast-feeding </strong></p><p>Do not take Cellona if you are breast-feeding. This is because small amounts of the medicine can pass into the mother&rsquo;s milk.</p><p><strong>Driving and using machines </strong></p><p>Cellona is not likely to affect you being able to drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Cellona exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take</strong></p><p>The amount you take depends on the type of transplant you have had. The usual doses are shown below. Treatment will continue for as long as you need to prevent you from rejecting your transplant organ.</p><p><u><strong>Kidney transplant</strong></u></p><p><u>Adults</u></p><p>&bull; The first dose is given within 3 days of the transplant operation.</p><p>&bull; The daily dose is 4 tablets Cellona 500 mg or 8 tablets Cellona 250 mg (2 g of the medicine) taken as 2 separate doses.</p><p>&bull; Take 2 tablets Cellona 500 mg or 4 tablets Cellona 250 mg in the morning and then 2 tablets Cellona 500 mg or 4 tablets Cellona 250 mg in the evening. Children (aged 2 to 18 years) &bull; The dose given will vary depending on the size of the child.</p><p>&bull; Your doctor will decide the most appropriate dose based on your child&rsquo;s height and weight (body surface area &ndash; measured as square metres or &ldquo;m2 &rdquo;). The recommended dose is 600 mg/ m&sup2; taken twice a day.</p><p>&nbsp;</p><p><strong>Heart transplant </strong></p><p><u>Adults </u></p><p>&bull; The first dose is given within 5 days of the transplant operation.</p><p>&bull; The daily dose is 6 tablets Cellona 500 mg or 12 tablets Cellona 250 mg (3 g of the medicine) taken as 2 separate doses.</p><p>&bull; Take 3 tablets Cellona 500 mg or 6 tablets Cellona 250 mg in the morning and then Take 3 tablets Cellona 500 mg or 6 tablets Cellona 250 mg in the evening. Children</p><p>&bull; There is no information for the use of Cellona in children with a heart transplant.</p><p><strong>Liver transplant</strong></p><p><u>Adults</u></p><p>&bull; The first dose of oral Cellona will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines.</p><p>&bull; The daily dose is 6 tablets Cellona 500 mg or 12 tablets Cellona 250 mg (3 g of the medicine) taken as 2 separate doses.</p><p>&bull; Take 3 tablets Cellona 500 mg or 6 tablets Cellona 250 mg in the morning and then 3 tablets Cellona 500 mg or 6 tablets Cellona 250 mg in the evening</p><p><u>Children</u></p><p>&bull; There is no information for the use of Cellona in children with a liver transplant.</p><p><strong>Taking the medicine</strong></p><p>&bull; Swallow your tablets whole with a glass of water</p><p>&bull; Do not break or crush them</p><p><strong>If you take more Cellona than you should </strong></p><p><strong>I</strong>f you take more Cellona than you should, talk to a doctor or go to a hospital straight away. Also do this if someone else accidentally takes your medicine. Take the medicine pack with you.</p><p><strong>If you forget to take Cellona</strong></p><p>If you forget to take your medicine at any time, take it as soon as you remember. Then continue to take it at the usual times. Do not take a double dose to make up for a missed dose.</p><p><strong>If you stop taking Cellona</strong></p><p>Do not stop taking Cellona unless your doctor tells you to. If you stop your treatment you may increase the chance of rejection of your transplanted organ.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Talk to a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p>&bull; You have a sign of infection such as a fever or sore throat</p><p>&bull; You have any unexpected bruising or bleeding</p><p>&bull; You have a rash, swelling of your face, lips, tongue or throat, with difficulty breathing - you may be having a serious allergic reaction to the medicine (such as anaphylaxis, angioeodema).</p><p><strong>Usual problems </strong></p><p>Some of the more usual problems are diarrhoea, fewer white cells or red cells in your blood, infection and vomiting. Your doctor will do regular blood tests to check for any changes in:</p><p>&bull; The number of your blood cells</p><p>&bull; The amount in your blood of things like sugar, fat or cholesterol.</p><p>Children may be more likely than adults to have some side effects. These include diarrhoea, infections, fewer white cells and fewer red cells in the blood.</p><p><strong>Fighting infections </strong></p><p>Cellona reduces your body&rsquo;s defenses. This is to stop you rejecting your transplant. As a result, your body will not be as good as normal at fighting infections. This means you may catch more infections than usual. This includes infections of the brain, skin, mouth, stomach and gut, lungs and urinary system.</p><p><strong>Lymph and skin cancer</strong></p><p>As can happen in patients taking this type of medicine (immune-suppressants), a very small number of Cellona patients have developed cancer of the lymphoid tissues and skin.</p><p><strong>General unwanted effects</strong></p><p>You may get general side effects affecting your body as a whole. These include serious allergic reactions (such as anaphylaxis, angioeodema), fever, feeling very tired, difficulty sleeping, pains (such as stomach, chest, joint or muscle, pain on passing urine), headache, flu symptoms and swelling.</p><p>Other unwanted effects may include:</p><p><strong>Skin problems such as: </strong>&bull; Acne, cold sores, shingles, skin growth, hair loss, rash, itching</p><p><strong>Urinary problems such as: </strong>&bull; Kidney problems or the urgent need to pass water (urine).</p><p><strong>Digestive system and mouth problems such as:</strong></p><p>&bull; Swelling of the gums and mouth ulcers</p><p>&bull; Inflammation of the pancreas, colon or stomach</p><p>&bull; Gut problems including bleeding, liver problems</p><p>&bull; Constipation, feeling sick (nausea), indigestion, loss of appetite, flatulence.</p><p><strong>Nervous system problems such as:</strong></p><p>&bull; Feeling dizzy, drowsy or numb</p><p>&bull; Tremor, muscle spasms, convulsions</p><p>&bull; Feeling anxious or depressed, changes in your mood or thoughts.</p><p><strong>Heart and blood vessel problems such as:</strong> &bull; Change in blood pressure, unusual heartbeat, widening of blood vessels.</p><p><strong>Lung problems such as:</strong></p><p>&bull; Pneumonia, bronchitis</p><p>&bull; Shortness of breath, cough which can be due to bronchiectasis (a condition in which the lung airways are abnormally dilated) or pulmonary fibrosis (scarring of the lung). Talk to your doctor if you develop a persistent cough or breathlessness</p><p>&bull; Fluid on the lungs or inside the chest</p><p>&bull; Sinus problems</p><p><strong>Other problems such as:</strong></p><p>&bull; Weight loss, gout, high blood sugar, bleeding, bruising. If you get any side effects, talk to your doctor or nurse.</p><p>This includes any possible side effects not listed in this leaflet.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C. Keep this medicine out of the sight and reach of children. Do not use Cellona after the expiry date which is stated on the carton and blister, after EXP. The expiry date refers to the last day of the month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is mycophenolate mofetil.</p><p>For Cellona 250 mg</p><p>Each tablet contains 250 mg of mycophenolate mofetil.</p><p>For Cellona 500 mg</p><p>Each tablet contains 500 mg of mycophenolate mofetil.</p><p>- &quot;Cellona 250 mg&quot; &amp; &quot;Cellona 500 mg&quot; both contain other ingredients are:</p><p>&bull; Tablet nucleus: microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate.</p><p>&bull; Tablet coating: hypromellose 3 cP, hydroxypropylcellulose, titanium dioxide (E171), macrogol 400, hypromellose 50 cP, indigo carmine aluminium lake (E132), red iron oxide (E172).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                "Cellona 250 mg" & "Cellona 500 mg" tablets are presented as oblong, violet, film-coated
tablets.
They are available as blisters (VPOA 10400 / Alum.)
Cellona 250 mg: 300 film-coated tablets per pack.
Cellona 500mg: 150 film-coated tablets per pack. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by Ko&ccedil;ak Farma Turkey For Al-Qassim Pharmaceutical Plant Saudi ArabiaManufactured by Ko&ccedil;ak Farma Turkey For Al-Qassim Pharmaceutical Plant Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2019. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>سيللونا هو مستحضر دوائي يحتوي على مادة فعالة تسمى ميكوفينوالت موفتيل. &bull; تنتمي هذه المادة إلى مجموعة من األدوية تسمى &quot;مثبطات المناعة.&quot; تستخدم أقراص سيللونا لمنع جسمك من رفض العضو المزروع.</p><p>&bull; قد يكون هذا العضو المزروع كليه أو قلب أو كبد.</p><p>أقراص سيللونا ينبغي أن تستخدم جنبا إلى جنب مع أدوية أخرى:</p><p>&bull; سيكلوسبورين</p><p>&bull; كورتيزون</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تحذير ميكوفينوالت تسبب عيوباً خلقية بالمواليد وتسبب إجهاض. إذا كن ت امرأة يمكن أن تصبحي حامالً، فيجب علي ك تقديم نتيجة سلبية الختبار الحمل قبل البدء فى تناول العالج وعلي ك اتباع نصيحة منع الحمل التي قدمها ل ك طبيبك المعالج.سيتحدث معك طبيبك المعالج وسيقدم لك معلومات مكتوبة، خاصةً حول تأثيرات ميكوفينوالت على األطفال الذين لم تتم والدتهم بعد. يرجى قراءة المعلومات بعناية واتباع التعليمات. فى حالة عدم الفهم التام لهذه التعليمات، فيرجى مطالبة طبيبك المعالج بشرحها مرة أخرى قبل تناول ميكوفينوالت. ا مزيد من المعلومات في هذا القسم تحت عنوان &quot;التحذيرات واالحتياطات&quot; و &quot;الحمل والرضاعة ً انظر أيض الطبيعية&quot;</p><p>ال تتناول أقراص سيللونا في أي من الحاالت اآلتية:</p><p>&bull; لديك حساسية من مادة ميكوفينوالت موفتيل، حامض الميكوفينوليك أو أي من المكونات األخرى في سيللونا )المذكورة في القسم 6.)</p><p>&bull; إذا كن ت امرأة ولدي ك احتمالية حدوث حمل ولم تقومي بتقديم نتيجة سلبية الختبار الحمل قبل وصفتك الطبية األولى حيث أن ميكوفينوالت يسبب تشوهات خلقية للجنين ويسبب اإلجهاض. أو تخططين للحمل أو تظنين أن ك حامل.</p><p>&bull; إذا كن ت حامالً</p><p>&bull; إذا كن ت ال تستخدمين وسائل منع الحمل الفعالة )انظرى فقرة الحمل، وسائل منع الحمل والرضاعة الطبيعية(. .</p><p>&bull; إذا كن ت ترضعين طفلك طبيعي</p><p>ال تتناول هذا الدواء إذا كان أي من الحاالت أعاله تنطبق عليك. إذا لم تكن متأكدا، أخبر طبيبك أو الصيدالني قبل تناول سيللونا .</p><p><strong>التحذيرات واالحتياطات</strong></p><p>أخبر طبيبك المعالج فورا قبل البدء في تناول أقراص سيللونا إذا:</p><p>&bull; كان لديك أي عرض يدل على اإلصابة بعدوى مثل الحمى أو التهاب الحلق.</p><p>&bull; كان لديك أي كدمات أو نزيف غير متوقع.</p><p>&bull; كان لديك في أي وقت مشكلة في الجهاز الهضمي مثل قرحة في المعدة.</p><p>&bull; كن ت تخططين لتصبحي حامال أو إذا أصبح ت حامال أثناء تناول سيللونا . فورا قبل تناول أقراص ً إذا كان أي من الحاالت أعاله تنطبق عليك )أو لم تكن متأكدا(، أخبر طبيبك أو الصيدالني سيللونا</p><p><strong>تأثير آشعة الشمس</strong></p><p>سيللونا يقلل من الطرق الدفاعية لجسمك. و نتيجة لذلك، تزيد نسبة خطر اإلصابة بسرطان الجلد. حاول الحد من كمية آشعة الشمس واآلشعة فوق البنفسجية التي تتعرض لها و ذلك عن طريق:</p><p>&bull; ارتداء المالبس الواقية التي تغطي أيضاً الرأس و العنق و الذراعين و الساقين.</p><p>&bull; استخدام واقي من آشعة الشمس يحتوى على عامل حماية عالي.</p><p><strong>سيللونا و األدوية األخرى</strong></p><p>&nbsp;</p><p>رجا ًء أخبر طبيبك المعالج بشأن أي أدوية أخرى تناولتها مؤخراً بدون وصفة طبية، و األدوية التي تحتوي على أعشاب. و ذلك ألن سيللونا قد يؤثر على طريقة عمل بعض األدوية، و أيضا أدوية أخرى قد تؤثر على طريقة عمل سيللونا. ً على وجه الخصوص، أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول أياًمن هذه األدوية قبل البدء بتناول سيللونا:</p><p>&bull; آزاثيوبرين أو غيرها من األدوية التي تعمل على تثبيط الجهاز المناعي )والتي تستخدم بعد عملية زراعة األعضاء(.</p><p>&bull; كوليستيرامين )يستخدم لعالج ارتفاع نسبة الكوليسترول في الدم(.</p><p>&bull; ريفامبيسين )مضاد حيوي يستخدم لمكافحة وعالج العدوى مثل مرض السل(.</p><p>&bull; مضادات الحموضة، أو مثبطات مضخة البروتون - تستخدم لعالج مشاكل الحمض الموجود في المعدة مثل عسر الهضم. &bull; ممسكات الفوسفات )المستخدمة من قبل األشخاص الذين يعانون من الفشل الكلوي المزمن للحد من كمية الفوسفات التي تمتص إلى الدم(.</p><p>&bull; المضادات الحيوية &ndash; والتي تستخدم لعالج العدوى البكتيرية.</p><p>&bull; إيزافوكونازول &ndash; والذي يستخدم لعالج العدوى الفطرية.</p><p>&bull; تلميسارتان &ndash; والذي يستخدم لعالج ارتفاع ضغط الدم</p><p><strong>اللقاحات</strong></p><p>&nbsp;سينصحك طبيبك بأنواع إذا كنت بحاجة إلى لقاح )لقاح حي( أثناء تناولك سيللونا، أخبر طبيبك أو الصيدلي أوالً اللقاحات التي يمكنك الحصول عليها. يجب عليك عدم التبرع بالدم أثناء فترة العالج بواسطة سيللونا ولمدة 6 أسابيع على األقل بعد وقف العالج. يجب على يوما ً الرجال عدم التبرع بالمني أثناء فترة العالج بواسطة سيللونا ولمدة 90 على األقل بعد التوقف عن العالج</p><p>&nbsp;</p><p><strong>سيللونا مع الطعام والشراب</strong></p><p>تناول الطعام والشراب ليس له أي تأثير على عالجك بأقراص سيللونا .</p><p><strong>الحمل، موانع الحمل والرضاعة</strong></p><p><strong>موانع الحمل عند النساء الالئي يتناولن سيللونا</strong></p><p>ذا كن ت امرأة معرضة الحتمالية حدوث الحمل، يجب علي ك استخدام وسيلة فعالة لمنع الحمل مع سيللونا. هذا يشمل:</p><p>&bull; قبل البدء في تناول سيللونا.</p><p>&bull; خالل فترة العالج بالكامل بواسطة سيللونا.</p><p>&bull; لمدة 6 أسابيع بعد التوقف عن تناول سيللونا.</p><p><u>تواصلي مع طبيبك المعالج بشأن أنسب وسائل منع الحمل بالنسبة لك. هذا يعتمد على وضعك بشكل خاص. هناك نوعان من وسائل منع الحمل هما األفضل ألن هذا سيقلل من خطر الحمل غير المقصود. اتصلي بطبيبك المعالج في أقرب وقت ممكن</u>،<strong> إذا كن ِت تعتقدين أن وسائل منع الحمل الخاصة بك قد ال تكون فعالة أو إذا نسي ِت تناول حبوب منع الحمل.</strong></p><p>فى حالة انطباق أى مما يلي علي ك, فأن ت من النساء الغير قادرات على الحمل:</p><p>&bull; إذا كن ت في مرحلة ما بعد انقطاع الطمث، بمعنى ما ال يقل عن 50 عاماًمن العمر وكانت آخر دورة شهرية لدي ك قبل أكثر من عام )إذا توقفت الدورة الشهرية بسبب حصولك على عالج من السرطان، فال تزال هناك فرصة ألن تصبحي حامالً(.</p><p>&bull; إذا تعرض ت إلى إزالة أنابيب فالوب وكال المبيضين عن طريق الجراحة.</p><p>&bull; إذا تعرض ت إلى استئصال الرحم عن طريق الجراحة.</p><p>&bull; إذا لم تعد تعمل لدي ك المبايض )فشل المبيض السابق ألوانه، والذي تم تأكيده من خالل طبيب أمراض النساء المتخصص(.</p><p>&bull; إذا كن ت قد ولد ت بإحدى الحاالت النادرة التالية التي تجعل الحمل مستحيالً: النمط الوراثي XY ،أو متالزمة تيرنر، أو التورم الرحمي.</p><p>&bull; إذا كن ت من األطفال أو المراهقين ممن لم تبدأ لديهن الدورة الشهرية بعد.</p><p><strong>وسائل منع الحمل عند الرجال الذين يتناولون سيللونا</strong></p><p>ال تشير األدلة المتاحة إلى زيادة خطر حدوث تشوهات للجنين أو حدوث إجهاض فى حالة عالج األب بواسطة ميكوفينوالت. ومع ذلك، ال يمكن استبعاد الخطر بالكامل. كإجراء وقائي، ي نصح الزوج أو الزوجة ب استخدام وسائل منع الحمل الموثوقة أثناء فترة العالج ولمدة 90 يوماً بعد التوقف عن تناول سيللونا. إذا كنت تخطط إلنجاب طفل، تحدث إلى طبيبك المعالج حول المخاطر المحتملة.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>أو تخططين إلنجاب طفل، اسألي طبيبك أو ترضعين طفلك طبيعياً، أو تعتقدين أن ك قد تكوني حامالً إذا كن ت حامالً المعالج أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء. سيتحدث معك طبيبك المعالج حول المخاطر في حالة الحمل والبدائل التي يمكنك اتخاذها لمنع رفض العضو المزروع في الحاالت اآلتية:</p><p>&bull; إذا كن ت تخططين للحمل.</p><p>&bull; إذا فاتتك دورة شهرية أو تعتقدين ذلك، أو كن ت تعانين من نزيف حيض غير عادي، أو لدي ك شك في أن ك حامل.</p><p>&bull; فى حالة ممارسة الجنس دون استخدام وسيلة فعالة لمنع الحمل. حامالً فترة العالج بواسطة ميكوفينوالت، فيجب علي ك إبالغ طبيبك المعالج على الفور. ومع ذلك، إذا أصبح ت أثناء يجب علي ك االستمرار فى تناول سيللونا حتى رؤيتك للطبيب المعالج.&nbsp;</p><p><strong>الحمل</strong></p><p>دا 50 )وحدوث حاالت عيوب خلقية شديدة ً يتسبب ميكوفينوالت في حدوث عدد كبير ج من حاالت اإلجهاض )% باألجنة )23-27 .)%العيوب الخلقية التي تم اإلبالغ عنها تشمل شذوذ األذنين والعينين والوجه )شق الشفة / شق الحنك( وخلل في نمو األصابع والقلب والمريء )وهو األنبوب الذي يربط الحلق بالمعدة( وخلل في الكلى والجهاز العصبي )على سبيل المثال السنسنة المشقوقة )حيث لم يتم تكوين عظام العمود الفقري بشكل صحيح((. قد يتأثر طفلك بواحد أو أكثر من تلك التأثيرات.&nbsp;إذا كن ت امرأة معرضة لحدوث حمل، فيجب علي ك تقديم نتيجة سلبية الختبار الحمل قبل البدء فى تناول هذا العالج وعلي ك اتباع نصيحة منع الحمل التي قدمها لك طبيبك المعالج. قد يطلب طبيبك المعالج أكثر من اختبار واحد للتأكد من أنك لس ت حامالً قبل بدء العالج.</p><p><strong>الرضاعة الطبيعية</strong></p><p>ال تتناولي سيللونا إذا كن ت ترضعين طفلك رضاعة طبيعية. و ذلك ألن كميات صغيرة من الدواء يمكن أن تنتقل إلى حليب األم.</p><p><strong>القيادة واستخدام اآلالت</strong></p><p>من غير المرجح أن سيللونا سوف يؤثر على قدرتك على القيادة أو استعمال اآلالت واألدوات المختلفة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول سيللونا تماما كما اخبرك الطبيب . يجب عليك مراجعة الطبيب او الصيدلي اذا لم تكن متاكدا&nbsp;</p><p><strong>الجرعة</strong></p><p>الجرعة تعتمد على نوع زراعة العضو التي قمت بها. والجرعات المعتادة موضحة أدناه. سوف يستمر العالج لطالما كنت بحاجة إلى منع جسمك من رفض العضو المزروع.&nbsp;</p><p><strong>زراعة الكلى</strong></p><p><u>الكبار</u></p><p>&bull; تعطى الجرعة األولى في غضون 3 أيام من عملية الزرع. &bull; الجرعة اليومية 4 أقراص سيللونا 500 ملجم أو 8 أقراص سيللونا 250 ملجم )2 جرام من الدواء( تؤخذ على جرعتين منفصلتين. &bull; تناول قرصين سيللونا 500 ملجم أو 4 أقراص سيللونا 250 ملجم في الصباح ثم قرصين سيللونا 500 ملجم أو 4 أقراص سيللونا 250 ملجم في المساء</p><p><u>. األطفال</u> &nbsp;)الذين تتراوح أعمارهم بين 2-18 سنة(</p><p>&bull; إن الجرعة سوف تختلف تبعاً لحجم الطفل.</p><p>&bull; طبيبك سوف يقرر الجرعة األنسب على أساس طول و وزن طفلك )مساحة سطح الجسم - تقاس بالمتر مربع( الجرعة الموصى بها هي 600 ملجم / متر مربع، تؤخذ مرتين في اليوم.</p><p>&nbsp;</p><p><strong>زراعة القلب </strong></p><p><u>الكبار</u></p><p>&bull; تعطى الجرعة األولى خالل 5 أيام من عملية الزرع.</p><p>&bull; الجرعة اليومية هي 6 أقراص سيللونا 500 ملجم أو 12 قرص سيللونا 250 ملجم )3 جرام من الدواء( تؤخذ على جرعتين منفصلتين.</p><p>&bull; تناول 3 أقراص سيللونا 500 ملجم أو 6 أقراص سيللونا 250 ملجم في الصباح ثم 3 أقراص سيللونا 500 ملجم أو 6 أقراص سيللونا 250 ملجم في المساء.</p><p><u>األطفال</u></p><p>&bull; ليس هناك معلومات عن استخدام سيللونا في األطفال الذين خضعوا لعملية زراعة قلب.</p><p><strong>زراعة الكبد</strong></p><p><u>الكبار</u></p><p>&bull; سيتم إعطاء الجرعة األولى من سيللونا عن طريق الفم بعد 4 أيام على األقل من عملية الزراع ة وعندما تكون قادرا على ابتالع األدوية عن طريق الفم. ً</p><p>&bull; الجرعة اليومية هي 6 أقراص سيللونا 500 ملجم أو 12 قرص سيللونا 250 ملجم )3 جرام من الدواء( تؤخذ على جرعتين منفصلتين.</p><p>&bull; خذ 3 أقراص سيللونا 500 ملجم أو 6 أقراص سيللونا 250 ملجم في الصباح ثم 3 أقراص سيللونا 500 ملجم أو 6 أقراص سيللونا 250 ملجم في المساء.</p><p><u>األطفال</u></p><p>&bull; ليس هناك معلومات عن استخدام سيللونا في األطفال الذين خضعوا لعملية زراعة كبد.</p><p><strong>تناول الدواء </strong></p><p>&bull; ابلع األقراص كاملة مع كوب من الماء.</p><p>&bull; ال تكسر أو تسحق األقراص.</p><p><strong>إذا تناولت أكثر مما يجب من أقراص سيللونا</strong></p><p>أيضا القيام ً إذا تناولت أكثر مما يجب من أقراص سيللونا، أخبر الطبيب أو توجه إلى المستشفى على الفور. عليك بذلك إذا تناول شخص آخر دوائك عن طريق الخطأ. أحضر العبوة معك.</p><p>&nbsp;</p><p><strong>إذا كنت قد نسيت أن تتناول سيللونا</strong></p><p>إذا كنت قد نسيت تناول دوائك في أي وقت، تناوله حالما تتذكر. ثم استمر في تناوله في األوقات المعتادة. ال تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p><strong>إذا توقفت عن تناول سيللونا </strong></p><p>ال تتوقف عن تناول سيللونا إال إذا طلب منك طبيبك ذلك. إذا توقفت عن العالج قد تزيد من فرصة رفض العضو المزروع لك. إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع األدوية، يمكن لهذا الدواء أن يسبب أعراضاً جانبية، وإن لم تكن تحدث لكل من يتناول هذا الدواء.&nbsp;</p><p><strong>أخبر الطبيب فوراً إذا الحظت أياً من األعراض الجانبية التالية - فقد تحتاج إلى تدخل طبي عاجل:</strong></p><p>&bull; لديك أي عرض يدل على اإلصابة بالعدوى مثل الحمى أو التهاب الحلق.</p><p>&bull; لديك أي كدمات أو نزيف غير متوقع. بفرط</p><p>&bull; لديك طفح جلدي، ورم في الوجه، الشفتين، اللسان أو الحلق، مع صعوبة في التنفس. قد تكون مصاباً تحسس خطير تجاه هذا الدواء )مثل: الحساسية المفرطة أو وذمة وعائية(.</p><p><strong>األعراض المعتادة</strong></p><p>بعض من أكثر األعراض المعتادة هي اإلسهال، وقلة عدد الخاليا البيضاء أو خاليا الدم الحمراء في دمك، والعدوى والقيء. طبيبك سوف يجرى اختبارات الدم المعتادة للتحقق من أي تغييرات في:</p><p>&bull; عدد الخاليا في الدم.</p><p>&bull; بعض النسب في الدم مثل السكر أو الدهون أو الكوليسترول. قد يكون األطفال أكثر عرضة من البالغين لألعراض الجانبية. وتشمل هذه األعراض اإلسهال، التهابات، قلة عدد الخاليا البيضاء و الحمراء في الدم.</p><p><strong>مكافحة العدوى</strong></p><p>سيللونا يقلل من مناعة الجسم. وهذا من أجل منع الجسم من رفض العضو المزروع. و نتيجة لذلك، لن يكون جسمك بقدرته الطبيعية على مكافحة العدوى. هذا يعني أنك قد تصاب بالمزيد من العدوى أكثر من المعتاد. وهذا يشمل التهابات في الدماغ والجلد والفم والمعدة واألمعاء والرئتين والجهاز البولي</p><p><strong>سرطان الجلد واألنسجة اللمفاوية</strong></p><p>كما يمكن أن يحدث في المرضى الذين يتناولون هذا النوع من األدوية )مثبطات المناعة(، عدد قليل جداً من المرضى الذين تناولوا سيللونا أصيبوا بسرطان األنسجة اللمفاوية والجلد.</p><p><strong>أعراض عامة غير مرغوب فيها</strong></p><p>قد تتعرض ألعراض جانبية عامة تؤثر على الجسم ككل. وتشمل هذه األعراض حاالت فرط تحسس خطيرة )مثل:</p><p>الحساسية المفرطة أو وذمة وعائية(، وحمى، والشعور بالتعب الشديد، و صعوبة في النوم، وآالم )مثل المعدة والصدر والمفاصل أو العضالت، وآالم عند التبول(، والصداع، وأعراض األنفلونزا والتورم. قد تشمل األعراض األخرى غير المرغوب فيها:</p><p><strong>أعراض الجلد مثل: </strong>&bull; حب الشباب، والقروح الباردة، القوباء المنطقية، ونمو الجلد، وتساقط الشعر، والطفح الجلدي، والحكة.</p><p><strong>أعراض المسالك البولية مثل:</strong> &bull; مشاكل الكلى أو الحاجة الملحة إلى التبول.</p><p><strong>أعراض الجهاز الهضمي والفم مثل:</strong></p><p>&bull; تورم في اللثة وتقرحات الفم. &bull; التهاب البنكرياس أو القولون أو المعدة.</p><p>&bull; مشاكل القناة الهضمية بما في ذلك النزيف، مشاكل في الكبد.</p><p>&bull; اإلمساك، والشعور بالمرض )الغثيان(، وعسر الهضم وفقدان الشهية، وانتفاخ البطن.</p><p><strong>اعراض الجهاز العصبي مثل</strong>: &bull;الشعور بالدوار، النعاس أو خدر. &bull;الرعشة، تشنجات العضالت، تشنجات. &bull;الشعور بالقلق أو االكتئاب، اضطرابات في المزاج أو األفكار</p><p><strong>أعراض القلب واألوعية الدموية مثل:</strong> &bull; تغير في ضغط الدم، وخلل في ضربات القلب، واتساع األوعية الدموية.</p><p><strong>أعراض الرئة مثل:</strong></p><p>&bull; االلتهاب الرئوي والتهاب الشعب الهوائية.</p><p>&bull; ضيق في التنفس، والسعال مما يمكن أن يكون نتيجة لتوسع القصبات )حالة مرضية تكون فيها الممرات الرئوية متسعة بشكل غير طبيعي(، أو التليف الرئوي )تندب الرئة(. أخبر طبيبك إذا تعرضت لسعال مستمر أو ضيق في التنفس.</p><p>&bull; وجود سوائل في الرئتين أو داخل الصدر. &bull; مشاكل الجيوب األنفية.</p><p><strong>أعراض أخرى مثل: </strong>&bull; فقدان الوزن، والنقرس، وارتفاع نسبة السكر في الدم، والنزيف، وكدمات. إذا تعرضت ألي أعراض جانبية، أخبر طبيبك أو الممرضة. ويشمل ذلك أي أعراض جانبية محتملة غير المذكورة في هذه النشرة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ في درجة حرارة أقل من 30 درجة مئوية. بعيدا عن نظر ومتناول األطفال. ً يحفظ هذا الدواء بأن تاريخ انتهاء الصالحية ال تستخدم سيللونا بعد انتهاء تاريخ الصالحية المسجل على الكرتون والشريط، علماً يشير إلى اليوم األخير من الشهر المذكور. ال تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من األدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي ميكوفينوالت موفتيل.</p><p>o سيللونا 250 ملجم</p><p>كل قرص يحتوي على 250 ملجم من ميكوفينوالت موفتيل.</p><p>o سيللونا 500 ملجم</p><p>كل قرص يحتوي على 500 ملجم من ميكوفينوالت موفتيل.</p><p>&bull; &quot;سيللونا 250ملجم&quot; و&quot; سيللونا 500ملجم&quot; كالهما يحتوي على المكونات األخرى هي: ▪ نواة القرص: ميكرو كريستاالين السيليلوز، كروسكارميلوز الصوديوم، بوفيدون، ماغنيسوم استيرات.</p><p>▪ غالف القرص:</p><p>هايبروميلوز 3سي بى ،هيدروكسي بروبايل السيليلوز، وثانى اكسيد التيتانيوم )E171 ،)ماكروجول 400 ،هايبروميلوز 50 سي بي، صبغة األلمونيوم النيلية القرمزية )E132 ،)أكسيد الحديد األحمر .)E172(</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تتوفر أقراص &quot;سيللونا 250 ملجم&quot; وأقراص&quot; سيللونا 500 ملجم&quot; في شكل أقراص مغلفة مستطيلة بنفسجية اللون. سيللونا 250 ملجم: الكرتون يحتوى على 300 قرص مغلف بطبقة رقيقة في شرائط ألمونيوم. سيللونا 500 ملجم: الكرتون يحتوى على 150 قرص مغلف بطبقة رقيقة في شرائط ألمونيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>تصنيع كوتشاك فرما تركيا لصالح سبيماكو مصنع األدوية بالقصيم المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ مايو 2019 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cellona 250 mg film-coated tablets.
Cellona 500 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For Cellona 250 mg
Each tablet contains 250 mg of mycophenolate mofetil.
For Cellona 500 mg
Each tablet contains 500 mg of mycophenolate mofetil.
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Cellona tablets are oblong and violet, film-coated tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cellona is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Cellona should be initiated and maintained by appropriately qualified transplant specialists.</p><p><em><u>Posology </u></em></p><p><em>Use in renal transplant</em></p><p><em>Adults </em></p><p>Oral Cellona should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose). Paediatric population aged 2 to 18 years For Cellona 250 mg film-coated tablets: The recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily). Cellona capsules should only be prescribed to patients with a body surface area of at least 1.25 m2 . Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed Cellona capsules at a dose of 750 mg twice daily (1.5 g daily dose). Patients with a body surface area greater than 1.5 m2 may be prescribed Cellona capsules at a dose of 1 g twice daily (2 g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction.</p><p>FoCellona 500 mg film-coated tablets. The recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily). CellCept tablets should only be prescribed to patients with a body surface area greater than 1.5 m2 , at a dose of 1 g twice daily (2 g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction.</p><p><em>Paediatric population &lt; 2 years</em></p><p>There are limited safety and efficacy data in children below the age of 2 years. These are insufficient to make dosage recommendations and therefore use in this age group is not recommended.</p><p><em>Use in cardiac transplant</em></p><p>Adults</p><p>Oral Cellona should be initiated within 5 days following transplantation. The recommended dose in cardiac transplant patients is 1.5 g administered twice daily (3 g daily dose). Paediatric population No data are available for paediatric cardiac transplant patients.</p><p><em>Use in hepatic transplant</em></p><p><em>Adults </em></p><p>IV Cellona should be administered for the first 4 days following hepatic transplant, with oral Cellona initiated as soon after this as it can be tolerated. The recommended oral dose in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose).</p><p>Paediatric population</p><p>No data are available for paediatric hepatic transplant patients.</p><p><u>Use in special populations</u></p><p><u>Elderly</u></p><p>The recommended dose of 1 g administered twice a day for renal transplant patients and 1.5 g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly. Renal impairment In renal transplant patients with severe chronic renal impairment (glomerular filtration rate &lt; 25 mL/min/1.73 m2 ), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided. These patients should also be carefully observed. No dose adjustments are needed in patients experiencing delayed renal graft function postoperatively (see section 5.2). No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</p><p><u><em>Severe hepatic impairment</em></u></p><p>No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. No data are available for cardiac transplant patients with severe hepatic parenchymal disease.</p><p><u><em>Treatment during rejection episodes </em></u></p><p>Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Cellona is not required. There is no basis for Cellona dose adjustment following cardiac transplant rejection. No pharmacokinetic data are available during hepatic transplant rejection.</p><p><u>Method of administration</u></p><p>Oral administration. Precautions to be taken before handling or administering the medicinal product. Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Cellona tablets should not be crushed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Cellona should not be given to patients with hypersensitivity to mycophenolate mofetil,
mycophenolic acid or to any of the excipients listed in section 6.1. Hypersensitivity reactions to
Cellona have been observed (see section 4.8).
• Cellona should not be given to women of childbearing potential who are not using highly
effective contraception (see section 4.6).
• Cellona treatment should not be initiated in women of child bearing potential without providing
a pregnancy test result to rule out unintended use in pregnancy (see section 4.6).
• Cellona should not be used during pregnancy unless there is no suitable alternative treatment to
prevent transplant rejection (see section 4.6).
• Cellona should not be given to women who are breastfeeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neoplasms</u></p><p>Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Cellona, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. As general advice to minimise the risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p><u>Infections</u></p><p>Patients treated with immunosuppressants, including Cellona, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). Such infections include latent viral reactivation, such as hepatitis B or hepatitis C reactivation and infections caused by polyomaviruses (BK virus associated nephropathy, JC &nbsp;virus associated progressive multifocal leukoencephalopathy PML). Cases of hepatitis due to reactivation of hepatitis B or hepatitis C have been reported in carrier patients treated with immunosuppressants. These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms. There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving Cellona in combination with other immunosuppressants. In some of these cases switching Cellona to an alternative immunosuppressant resulted in serum IgG levels returning to normal. Patients on Cellona who develop recurrent infections should have their serum immunoglobulins measured. In cases of sustained, clinically relevant hypogammaglobulinaemia, appropriate clinical action should be considered taking into account the potent cytostatic effects that mycophenolic acid has on T- and B-lymphocytes. There have been published reports of bronchiectasis in adults and children who received Cellona in combination with other immunosuppressants. In some of these cases switching Cellona to another immunosuppressant resulted in improvement in respiratory symptoms. The risk of bronchiectasis may be linked to hypogammaglobulinaemia or to a direct effect on the lung. There have also been isolated reports of interstitial lung disease and pulmonary fibrosis, some of which were fatal (see section 4.8). It is recommended that patients who develop persistent pulmonary symptoms, such as cough and dyspnoea, are investigated.</p><p><u>Blood and immune system </u></p><p>Patients receiving Cellona should be monitored for neutropenia, which may be related to Cellona itself, concomitant medications, viral infections, or some combination of these causes. Patients taking Cellona should have complete blood counts weekly during the first month, twice monthly for the second and third months of treatment, then monthly through the first year. If neutropenia develops (absolute neutrophil count &lt; 1.3 x 103 /&micro;l), it may be appropriate to interrupt or discontinue Cellona. Cases of pure red cell aplasia (PRCA) have been reported in patients treated with Cellona in combination with other immunosuppressants. The mechanism for mycophenolate mofetil induced PRCA is unknown. PRCA may resolve with dose reduction or cessation of Cellona therapy. Changes to Cellona therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8). Patients receiving Cellona should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression. Patients should be advised that during treatment with Cellona, vaccinations may be less effective, and the use of live attenuated vaccines should be avoided (see section 4.5). Influenza vaccination may be of value. Prescribers should refer to national guidelines for influenza vaccination.</p><p><u>Gastro-intestinal </u></p><p>Cellona has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation.&nbsp;</p><p>Cellona should be administered with caution in patients with active serious digestive system disease. Cellona is an IMPDH (inosine monophosphate dehydrogenase) inhibitor. Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p><p><u>Interactions </u></p><p>Caution should be exercised when switching combination therapy from regimens containing immunosuppressants, which interfere with MPA enterohepatic recirculation, e.g. ciclosporin, to others devoid of this effect, e.g. tacrolimus, sirolimus, belatacept, or vice versa, as this might result in changes of MPA exposure. Drugs which interfere with MPA&#39;s enterohepatic cycle (e.g. cholestyramine, antibiotics) should be used with caution due to their potential to reduce the plasma level and efficacy of Cellona (see also section 4.5). Therapeutic drug monitoring of MPA may be appropriate when switching combination therapy (e.g. from ciclosporin to tacrolimus or vice versa) or to ensure adequate immunosuppression in patients with high immunological risk (e.g. risk of rejection, treatment with antibiotics). It is recommended that Cellona should not be administered concomitantly with azathioprine because such concomitant administration has not been studied. The risk/benefit ratio of mycophenolate mofetil in combination with sirolimus has not been established (see also section 4.5).</p><p><u>Special populations</u></p><p>Elderly patients may be at an increased risk of adverse events such as certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared with younger individuals (see section 4.8).</p><p><u>Teratogenic effects </u></p><p>Mycophenolate is a powerful human teratogen. Spontaneous abortion (rate of 45% to 49%) and congenital malformations (estimated rate of 23% to 27%) have been reported following MMF exposure during pregnancy. ThereforeCellona is contraindicated in pregnancy unless there are no suitable alternative treatments to prevent transplant rejection. Female patients of childbearing potential should be made aware of the risks and follow the recommendations provided in section 4.6 (e.g. contraceptive methods, pregnancy testing) prior to, during, and after therapy with Cellona. Physicians should ensure that women taking mycophenolate understand the risk of harm to the baby, the need for effective contraception, and the need to immediately consult their physician if there is a possibility of pregnancy.</p><p><u>Contraception</u> (see section 4.6)</p><p>Because of robust clinical evidence showing a high risk of abortion and congential malformations when mycophenolate mofetil is used in pregnancy every effort to avoid pregnancy during treatment should be taken. Therefore women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting Cellona therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred to minimise the potential for contraceptive failure and unintended pregnancy.For contraception advice for men see section 4.6.</p><p>&nbsp;</p><p><u>Educational materials</u></p><p>In order to assist patients in avoiding foetal exposure to mycophenolate and to provide additional important safety information, the Marketing Authorization holder will provide educational materials to healthcare professionals. The educational materials will reinforce the warnings about the teratogenicity of mycophenolate, provide advice on contraception before therapy is started and guidance on the need for pregnancy testing. Full patient information about the teratogenic risk and the pregnancy prevention measures should be given by the physician to women of childbearing potential and, as appropriate, to male patients. Additional precautions Patients should not donate blood during therapy or for at least 6 weeks following discontinuation of mycophenolate. Men should not donate semen during therapy or for 90 days following discontinuation of mycophenolate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Aciclovir</u></p><p>Higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovir in comparison to the administration of aciclovir alone. The changes in MPAG (the phenolic glucuronide of MPA) pharmacokinetics (MPAG increased by 8%) were minimal and are not considered clinically significant. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are aciclovir concentrations, the potential exists for mycophenolate mofetil and aciclovir, or its prodrugs, e.g. valaciclovir, to compete for tubular secretion and further increases in concentrations of both substances may occur.</p><p><u>Antacids and proton pump inhibitors (PPIs)</u></p><p>Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with Cellona. When comparing rates of transplant rejection or rates of graft loss between Cellona patients taking PPIs vs. Cellona patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when Cellona was co- administered with magnesium and aluminium hydroxides is considerably less than when Cellona was co-administered with PPIs.<u> Medicinal products that interfere with enterohepatic circulation (e.g. cholestyramine, ciclosporin A, antibiotics)</u></p><p>Caution should be used with medicinal products that interfere with enterohepatic circulation because of their potential to reduce the efficacy of Cellona.</p><p><em>Cholestyramine</em></p><p>Following single dose administration of 1.5 g of mycophenolate mofetil to normal healthy subjects pre-treated with 4 g TID of cholestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4 and section 5.2). Caution should be used during concomitant administration because of the potential to reduce efficacy of Cellona.</p><p><em>Ciclosporin A</em></p><p>Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil. In contrast, if concomitant ciclosporin treatment is stopped, an increase in MPA AUC of around 30% should be expected. CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30-50% in renal transplant patients treated with Cellona and CsA compared with patients receiving sirolimus or belatacept and similar doses of Cellona (see also section 4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to one of the immunosuppressants which does not interfere with MPA&acute;s enterohepatic cycle. Antibiotics eliminating &beta;-glucuronidase-producing bacteria in the intestine (e.g. aminoglycoside, cephalosporin, fluoroquinolone, and penicillin classes of antibiotics) may interfere with MPAG/MPA enterohepatic recirculation thus leading to reduced systemic MPA exposure. Information concerning the following antibiotics is available:</p><p><em>Ciprofloxacin or amoxicillin plus clavulanic acid </em></p><p>Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal transplant recipients in the days immediately following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to cease within a few days of antibiotic discontinuation. The change in predose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of Cellona should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.</p><p><em>Norfloxacin and metronidazole</em></p><p>In healthy volunteers, no significant interaction was observed when Cellona was concomitantly administered with norfloxacin or metronidazole separately. However, norfloxacin and metronidazole combined reduced the MPA exposure by approximately 30% following a single dose of Cellona.</p><p><em>Trimethoprim/sulfamethoxazole </em></p><p>No effect on the bioavailability of MPA was observed. <u>Medicinal products that affect glucuronidation (e.g. isavuconazole, telmisartan) Concomitant administration of drugs inhibiting glucuronidation of MPA may increase MPA exposure</u>.</p><p>Caution is therefore recommended when administering these drugs concomitantly with Cellona.</p><p><em>Isavuconazole </em></p><p>An increase of MPA AUC0-&infin; by 35% was observed with concomitant administration of isavuconazole.</p><p><em>Telmisartan </em></p><p>Concomitant administration of telmisartan and Cellona resulted in an approximately 30% decrease of MPA concentrations. Telmisartan changes MPA&#39;s elimination by enhancing PPAR gamma (peroxisome proliferator-activated receptor gamma) expression, which in turn results in an enhanced UGT1A9 expression and activity. When comparing rates of transplant rejection,&nbsp;rates of graft loss or adverse event profiles between Cellona patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic drug-drug interaction were seen.</p><p><u>Ganciclovir </u></p><p>Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of Cellona (see section 4.2) and ganciclovir, it is anticipated that coadministration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics is anticipated and Cellona dose adjustment is not required. In patients with renal impairment in whom Cellona and ganciclovir or its prodrugs, e.g. valganciclovir, are coadministered, the dose recommendations for ganciclovir should be observed and patients should be monitored carefully.</p><p><u>Oral contraceptives</u></p><p>The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by coadministration of Cellona (see also section 5.2).</p><p><u>Rifampicin</u></p><p>In patients not also taking ciclosporin, concomitant administration of Cellona and rifampicin resulted in a decrease in MPA exposure (AUC0-12h) of 18% to 70%. It is recommended to monitor MPA exposure levels and to adjust Cellona doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly.</p><p><u>Sevelamer</u></p><p>Decrease in MPA Cmax and AUC (0-12h) by 30% and 25%, respectively, were observed when Cellona was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection). It is recommended, however, to administer Cellona at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption of MPA. There are no data on Cellona with phosphate binders other than sevelamer.</p><p><u>Tacrolimus </u></p><p>In hepatic transplant patients initiated on Cellona and tacrolimus, the AUC and Cmax of MPA, the active metabolite of Cellona, were not significantly affected by co-administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of Cellona (1.5 g BID) were administered to hepatic transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by Cellona (see also section 4.4).</p><p><u>Live vaccines </u></p><p>Live vaccines should not be given to patients with an impaired immune response. The antibody response to other vaccines may be diminished (see also 4.4).</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p><p><u>Potential interaction</u></p><p>Co-administration of probenecid with mycophenolate mofetil in monkeys raises plasma AUC of MPAG by 3-fold. Thus, other substances known to undergo renal tubular secretion may compete with MPAG, and thereby raise&nbsp;plasma concentrations of MPAG or the other substance undergoing tubular secretion.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Pregnancy whilst taking mycophenolate must be avoided. Therefore women of childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting Cellona therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred.</p><p><u>Pregnancy </u></p><p>Cellona is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection. Treatment should not be initiated without providing a negative pregnancy test result to rule out unintended use in pregnancy (see section 4.3). Female patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counseled regarding pregnancy prevention, and planning. Before starting Cellona treatment, women of childbearing potential should have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL in order to exclude unintended exposure of the embryo to mycophenolate. It is recommended that the second test should be performed 8 &ndash; 10 days after the first test. For transplants from deceased donors, if it is not possible to perform two tests 8-10 days apart before treatment starts (because of the timing of transplant organ availability), a pregnancy test must be performed immediately before starting treatment and a further test performed 8-10 days later. Pregnancy tests should be repeated as clinically required (e.g. after any gap in contraception is reported. Results of all pregnancy tests should be discussed with the patient. Patients should be instructed to consult their physician immediately should pregnancy occur. Mycophenolate is a powerful human teratogen, with an increased risk of spontaneous abortions and congenital malformations in case of exposure during pregnancy; &bull; Spontaneous abortions have been reported in 45 to 49% of pregnant women exposed to mycophenolate mofetil, compared to a reported rate of between 12 and 33% in solid organ transplant patients treated with immunosuppressants other than mycophenolate mofetil. &bull; Based on literature reports, malformations occurred in 23 to 27% of live births in women exposed to mycophenolate mofetil during pregnancy (compared to 2 to 3 % of live births in the overall population and approximately 4 to 5% of live births in solid organ transplant recipients treated with immunosuppressants other than mycophenolate mofetil). Congenital malformations, including reports of multiple malformations, have been observed post-marketing in children of patients exposed to Cellona during pregnancy in combination with other immunosuppressants. The following malformations were most frequently reported:</p><p>&bull; Abnormalities of the ear (e.g. abnormally formed or absent external ear), external auditory canal artesia (middle ear); &bull; Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits; &bull; Abnormalities of the eye (e.g. coloboma); &bull; Congenital heart disease such as atrial and ventricular septal defects; &bull; Malformations of the fingers (e.g. polydactyly, syndactyly); &bull; Tracheo-Oesophageal malformations (e.g. oesophageal atresia); &bull; Nervous system malformations such as spina bifida; &bull; Renal abnormalities. In addition there have been isolated reports of the following malformations: &bull; Microphthalmia; &bull; congenital choroid plexus cyst; &bull; septum pellucidum agenesis; &bull; olfactory nerve agenesis. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p><u>Breast-feeding </u></p><p>Mycophenolate mofetil has been shown to be excreted in the milk of lactating rats. It is not known whether this substance is excreted in human milk. Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Cellona is contraindicated in nursing mothers (see section 4.3).</p><p><u>Men</u></p><p>Limited clinical evidence does not indicate an increased risk of malformations or miscarriage following paternal exposure to mycophenolate mofetil. MPA is a powerful teratogen. It is not known if MPA is present in semen. Calculations based on animal data show that the maximum amount of MPA that could potentially be transferred to woman is so low that it would be unlikely to have an effect. Mycophenolate has been shown to be genotoxic in animal studies at concentrations exceeding the human therapeutic exposures only by small margins such that the risk of genotoxic effects on sperm cells cannot completely be excluded. Therefore, the following precautionary measures are recommended: sexually active male patients or their female partners are recommended to use reliable contraception during treatment of the male patient and for at least 90 days after cessation of mycophenolate mofetil. Male patients of reproductive potential should be made aware of and discuss the potential risks of fathering a child with a qualified health-care professional.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. The pharmacodynamic profile and the reported adverse reactions indicate that an effect is unlikely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>The following undesirable effects cover adverse reactions from clinical trials </u></p><p>The principal adverse reactions associated with the administration of Cellona in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting, and there is evidence of a higher frequency of certain types of infections (see section 4.4).</p><p><em>Malignancies </em></p><p>Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Cellona, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). Lymphoproliferative disease or lymphoma developed in 0.6% of patients receiving Cellona (2 g or 3 g daily) in combination with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year. Non-melanoma skin carcinomas occurred in 3.6% of patients; other types of malignancy occurred in 1.1% of patients. Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3 years.</p><p><em>Opportunistic infections</em></p><p>All transplant patients are at increased risk of opportunistic infections; the risk increased with total immunosuppressive load (see section 4.4) The most common opportunistic infections in patients receiving Cellona (2 g or 3 g daily) with other immunosuppressants in controlled clinical trials in renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex. The proportion of patients with CMV viraemia/syndrome was 13.5%</p><p><em>Paediatric population</em></p><p>The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600 mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1 g Cellona twice daily. However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6 years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection.</p><p><em>Elderly </em></p><p>Elderly patients (&ge; 65 years) may generally be at increased risk of adverse reactions due to immunosuppression. Elderly patients receiving Cellona as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.</p><p>Other adverse reactions</p><p>Adverse reactions, probably or possibly related to Cellona, reported in &ge;1/10 and in &ge;1/100 to &lt;1/10 of patients treated with Cellona in the controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients are listed in the following table.</p><p><strong>Adverse Reactions, Probably or Possibly Related to Cellona, Reported in Patients Treated with Cellona in Renal, Cardiac and Hepatic Clinical Trials when Used in Combination with Ciclosporin and Corticosteroids</strong></p><p>Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:806px"><tbody><tr><td rowspan="1" colspan="2" style="width:356px"><strong>System organ class</strong></td><td style="width:446px"><strong>Adverse drug reactions</strong></td></tr><tr><td rowspan="2" style="width:171px">Infections and infestations</td><td style="width:185px">Very common</td><td style="width:446px">Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster</td></tr><tr><td style="width:185px">Common</td><td style="width:446px">Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis, rhinitis</td></tr><tr><td rowspan="2" style="width:171px">Neoplasms benign, malignant and unspecified (incl cysts and polyps)</td><td style="width:185px">Very common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Skin cancer, benign neoplasm of skin</td></tr><tr><td rowspan="2" style="width:171px">Blood and lymphatic system disorders</td><td style="width:185px">Very common</td><td style="width:446px">Leucopenia, thrombocytopenia, anaemia</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Pancytopenia, leukocytosis</td></tr><tr><td rowspan="2" style="width:171px">Metabolism and nutrition disorders</td><td style="width:185px">Very common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Acidosis, hyperkalaemia, hypokalaemia, hyperglycaemia, hypomagnesaemia, hypocalcaemia, hypercholesterolaemia, hyperlipidaemia, hypophosphataemia, hyperuricaemia, gout, anorexia</td></tr><tr><td rowspan="2" style="width:171px">Psychiatric disorders</td><td style="width:185px">Very common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Agitation, confusional state, depression, anxiety, thinking abnormal, insomnia</td></tr><tr><td rowspan="2" style="width:171px">Nervous system disorders</td><td style="width:185px">very common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Convulsion, hypertonia, tremor, somnolence, myasthenic syndrome, dizziness, headache, paraesthesia, dysgeusia</td></tr><tr><td rowspan="2" style="width:171px">Cardiac disorders</td><td style="width:185px">Very common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Tachycardia</td></tr><tr><td rowspan="2" style="width:171px">Vascular disorders</td><td style="width:185px">very&nbsp;common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Hypotension, hypertension, vasodilatation</td></tr><tr><td rowspan="2" style="width:171px">Respiratory, thoracic and mediastinal disorders</td><td style="width:185px">very&nbsp;common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Pleural effusion, dyspnoea, cough</td></tr><tr><td rowspan="2" style="width:171px">Gastrointestinal disorders</td><td style="width:185px">very&nbsp;common</td><td style="width:446px">Vomiting, abdominal pain, diarrhoea, nausea</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Gastrointestinal haemorrhage, peritonitis, ileus, colitis, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, stomatitis, constipation, dyspepsia, flatulence, eructation</td></tr><tr><td rowspan="2" style="width:171px">Hepatobiliary disorders</td><td style="width:185px">very&nbsp;common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Hepatitis, jaundice, hyperbilirubinaemia</td></tr><tr><td rowspan="2" style="width:171px">Skin and subcutaneous tissue disorders</td><td style="width:185px">very&nbsp;common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Skin hypertrophy, rash, acne, alopecia,</td></tr><tr><td rowspan="2" style="width:171px">Musculoskeletal and connective Tissue disorders</td><td style="width:185px">very&nbsp;common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Arthralgia</td></tr><tr><td rowspan="2" style="width:171px">Renal and urinary disorders</td><td style="width:185px">very&nbsp;common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Renal impairment</td></tr><tr><td rowspan="2" style="width:171px">General disorders and administration site conditions</td><td style="width:185px">very&nbsp;common</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common</td><td style="width:446px">Oedema, pyrexia, chills, pain, malaise, asthenia,</td></tr><tr><td rowspan="2" style="width:171px">Investigations</td><td style="width:185px">Very common&nbsp;</td><td style="width:446px">-</td></tr><tr><td style="width:185px">common&nbsp;</td><td style="width:446px">Hepatic enzyme increased, blood creatinine increased, blood lactate dehydrogenase increased, blood urea increased, blood alkaline phosphatase increased, weight decreased</td></tr></tbody></table><p>Note: 501 (2 g Cellona daily), 289 (3 g Cellona daily) and 277 (2 g IV / 3 g oral Cellona daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.<u> The following undesirable effects cover adverse reactions from post-marketing experience </u></p><p>The types of adverse reactions reported during post-marketing with Cellona are similar to those seen in the controlled renal, cardiac and hepatic transplant studies. Additional adverse reactions reported during post-marketing are described below with the frequencies reported within brackets if known.</p><p><em>Gastrointestinal</em></p><p>Gingival hyperplasia (&ge;1/100 to &lt;1/10), colitis including cytomegalovirus colitis, (&ge;1/100 to &lt;1/10), pancreatitis (&ge;1/100 to &lt;1/10) and intestinal villous atrophy</p><p><em>Infections </em></p><p>Serious life-threatening infections including meningitis, endocarditis, tuberculosis and atypical mycobacterial infection. Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Cellona.</p><p>Agranulocytosis (&ge;1/1000 to &lt;1/100) and neutropenia have been reported; therefore, regular monitoring of patients taking Cellona is advised (see section 4.4). There have been reports of aplastic anaemia and bone marrow depression in patients treated with Cellona, some of which have been fatal.</p><p><em>Blood and lymphatic system disorder</em></p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with Cellona (see section 4.4).</p><p>Isolated cases of abnormal neutrophil morphology, including the acquired Pelger-Huet anomaly, have been observed in patients treated with Cellona. These changes are not associated with impaired neutrophil function. These changes may suggest a &#39;left shift&#39; in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive Cellona.</p><p><em>Hypersensitivity </em></p><p>Hypersensitivity reactions, including angioneuroticoedema and anaphylactic reaction have been reported.</p><p><em>Pregnancy, puerperium and perinatal conditions </em></p><p>Cases of spontaneous abortions have been reported in patients exposed to mycophenolate mofetil, mainly in the first trimester, see section 4.6.</p><p><em>Congenital disorders</em></p><p>Congenital malformations have been observed post-marketing in children of patients exposed to Cellona in combination with other immunosuppressants, see section 4.6.</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>There have been isolated reports of interstitial lung disease and pulmonary fibrosis in patients treated with Cellona in combination with other immunosuppressants, some of which have been fatal. There have also been reports of bronchiectasis in children and adults (frequency not known).</p><p><em>Immune system disorders </em></p><p>Hypogammaglobulinaemia has been reported in patients receiving Cellona in combination with other immunosuppressants (frequency not known).&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>To report any side effect(s):</p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Hotline: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience. In many of these cases, no adverse events were reported. In those overdose cases in which adverse events were reported, the events fall within the known safety profile of the medicinal product. It is expected that an overdose of mycophenolate mofetil could possibly result in oversuppression of the immune system and increase susceptibility to infections and bone marrow suppression (see section 4.4). If neutropenia develops, dosing with Cellona should be interrupted or the dose reduced (see section 4.4). Haemodialysis would not be expected to remove clinically significant amounts of MPA or MPAG. Bile acid sequestrants, such as cholestyramine, can remove MPA by decreasing the enterohepatic re-circulation of the drug (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immunosuppressive agents ATC code L04AA06</p><p><u>Mechanism of action</u></p><p>Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA. MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines whereas other cell types can utilise salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption </u></p><p>Following oral administration, mycophenolate mofetil undergoes rapid and extensive absorption and complete presystemic metabolism to the active metabolite, MPA. As evidenced by suppression of acute rejection following renal transplantation, the immunosuppressant activity of Cellona is correlated with MPA concentration. The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94% relative to IV mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5 g BID to renal transplant patients. However, MPA Cmax was decreased by 40% in the presence of food. Mycophenolate mofetil is not measurable systemically in plasma following oral administration.</p><p><u>Distribution </u></p><p>As a result of enterohepatic recirculation, secondary increases in plasma MPA concentration are usually observed at approximately 6 &ndash; 12 hours post-dose. A reduction in the AUC of MPA of approximately 40% is associated with the co-administration of cholestyramine (4 g TID), indicating that there is a significant amount of enterohepatic recirculation. MPA at clinically relevant concentrations is 97% bound to plasma albumin.</p><p><u>Biotransformation</u></p><p>MPA is metabolised principally by glucuronyl transferase (isoform UGT1A9) to form the inactive phenolic glucuronide of MPA (MPAG). In vivo, MPAG is converted back to free MPA via enterohepatic recirculation. A minor acylglucuronide (AcMPAG) is also formed. AcMPAG is pharmacologically active and is suspected to be responsible for some of MMF&acute;s side effects (diarrhoea, leucopenia).</p><p><u>Elimination </u></p><p>A negligible amount of substance is excreted as MPA (&lt; 1 % of dose) in the urine. Oral administration of radiolabelled mycophenolate mofetil results in complete recovery of the administered dose with 93% of the administered dose recovered in the urine and 6% recovered in the faeces. Most (about 87%) of the administered dose is excreted in the urine as MPAG. At clinically encountered concentrations, MPA and MPAG are not removed by haemodialysis. However, at high MPAG plasma concentrations (&gt; 100&micro;g/mL), small amounts of MPAG are removed. By interfering with enterohepatic circulation of the drug, bile acid sequestrants such as cholestyramine, reduce MPA AUC (see section 4.9). MPA&#39;s disposition depends on several transporters. Organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA&#39;s disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides&#39; biliary excretion. Multidrug resistance protein 1 (MDR1) is also able to transport MPA, but its contribution seems to be confined to the absorption process. In the kidney MPA and its metabolites potently interact with renal organic anion transporters. In the early post-transplant period (&lt; 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 &ndash; 6 months post-transplant).</p><p><u>Special populations </u></p><p><em>Renal impairment</em></p><p>In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate &lt; 25 mL/min/ 1.73 m2 ) were 28 &ndash; 75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment. The mean single dose MPAG AUC was 3 &ndash; 6-fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG. Multiple dosing of mycophenolate mofetil in patients with severe chronic renal impairment has not been studied. No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</p><p><em>Delayed renal graft function </em></p><p>In patients with delayed renal graft function post-transplant, mean MPA AUC (0&ndash;12h) was comparable to that seen in post-transplant patients without delayed graft function. Mean plasma MPAG AUC (0-12h) was 2 &ndash; 3-fold higher than in post-transplant patients without delayed graft function. There may be a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function. Dose adjustment of Cellona does not appear to be necessary.</p><p><em>Hepatic impairment</em></p><p>In volunteers with alcoholic cirrhosis, hepatic MPA glucuronidation processes were relatively unaffected by hepatic parenchymal disease. Effects of hepatic disease on this process probably depend on the particular disease. However, hepatic disease with predominantly biliary damage, such as primary biliary cirrhosis, may show a different effect.</p><p><em>Paediatric population </em></p><p>Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients (aged 2 to 18 years) given 600 mg/m2 mycophenolate mofetil orally twice daily. This dose achieved MPA AUC values similar to those seen in adult renal transplant patients receiving Cellona at a dose of 1 g bid in the early and late post-transplant period. MPA AUC values across age groups were similar in the early and late post-transplant period.</p><p><em>Elderly </em></p><p>Pharmacokinetic behaviour of Cellona in the elderly (&ge; 65 years) has not been formally evaluated.</p><p><em>Patients taking oral contraceptives</em></p><p>A study of the co-administration of Cellona (1 g bid) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.15 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) conducted in 18 non-transplant women (not taking other immunosupressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of Cellona on the ovulation suppressing action of the oral contraceptives. Serum levels of LH, FSH and progesterone were not significantly affected. The pharmacokinetics of oral contraceptives were unaffected by co-administration of Cellona (see also section 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In experimental models, mycophenolate mofetil was not tumourigenic. The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 &ndash; 3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3 &ndash; 2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day. Two genotoxicity assays (in vitro mouse lymphoma assay and in vivo mouse bone marrow micronucleus test) showed a potential of mycophenolate mofetil to cause chromosomal aberrations. These effects can be related to the pharmacodynamic mode of action, i.e. inhibition of nucleotide synthesis in sensitive cells. Other in vitro tests for detection of gene mutation did not demonstrate genotoxic activity. Mycophenolate mofetil had no effect on fertility of male rats at oral doses up to 20 mg/kg/day. The systemic exposure at this dose represents 2 &ndash; 3 times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3 &ndash; 2 times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients. In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity. The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended&nbsp;clinical dose of 3 g/day for cardiac transplant patients. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation. In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at 6 mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity. The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients (see section 4.6). The haematopoietic and lymphoid systems were the primary organs affected in toxicology studies conducted with mycophenolate mofetil in the rat, mouse, dog and monkey. These effects occurred at systemic exposure levels that are equivalent to or less than the clinical exposure at the recommended dose of 2 g/day for renal transplant recipients. Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended dose. Gastrointestinal and renal effects consistent with dehydration were also observed in the monkey at the highest dose (systemic exposure levels equivalent to or greater than clinical exposure). The nonclinical toxicity profile of mycophenolate mofetil appears to be consistent with adverse events observed in human clinical trials which now provide safety data of more relevance to the patient population (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>tablet nucleus Microcrystalline cellulose Croscarmellose sodium Povidone Magnesium stearate table coating Hypromellose 3 cP Hydroxypropylcellulose Titanium dioxide (E171) Macrogol 400 Hypromellose 50 cP Indigo carmine aluminium lake (E132) Red iron oxide (E172) (Opadry Y-5R-10272-A Lavander)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&quot;Cellona 250 mg&quot; &amp; &quot;Cellona 500 mg&quot; tablets are presented as oblong, violet, film-coated tablets. They are available as blisters (VPOA 10400 / Alum.) Cellona 250 mg: 300 film-coated tablets per pack. Cellona500 mg: 150 film-coated tablets per pack.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Cellona film-coated tablets should not be crushed. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by
KoçakFarma Turkey
For
SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2019.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>